NMN Polyphenol Nutraceutical Composition Bioavailability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current nutraceutical compositions do not exhibit a synergistic effect in up-regulating SIRT1 expression, despite the potential benefits of combining nicotinamide mononucleotide (NMN) and polyphenols, which are known to enhance NAD+ levels and promote SIRT1 activity.

Innovation Solution

A nutraceutical composition combining NMN with a specific polyphenol and a soluble agent, such as quercetin or resveratrol, encapsulated in a protective bio-active agent like olive oil or yogurt, to increase bioavailability and protect the polyphenols during gut absorption, thereby enhancing SIRT1 expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If polyphenols are administered alone, then they provide antioxidant activity and health benefits, but they show low bioavailability due to interaction with food matrix and metabolic processes

Engineering Contradiction:
ImprovebioavailabilityVSAvoiddegradation during absorption
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses a protective bio-active agent as an intermediary substance that encapsulates polyphenols during gut absorption. This mediator protects polyphenols from degradation and interaction with the food matrix, enabling them to reach the bloodstream intact while maintaining their health benefits.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical-chemical parameters of polyphenol delivery by combining them with specific soluble agents and protective bio-active agents. This formulation approach modifies the bioavailability parameters, allowing polyphenols to withstand metabolic processes and achieve higher systemic levels.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If NMN and polyphenols are combined in nutraceutical compositions, then they may enhance NAD+ levels and promote SIRT1 activity, but current compositions do not exhibit synergistic effect due to low bioavailability of polyphenols

Engineering Contradiction:
Improvesynergistic effect on SIRT1 expressionVSAvoideffective concentration reaching target
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The protective bio-active agent serves as a mediator that enables the synergistic interaction between NMN and polyphenols by ensuring adequate concentrations of polyphenols reach the target tissues. Without this intermediary, polyphenol degradation prevents achieving the effective concentration needed for synergy.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent creates a composite nutraceutical formulation combining NMN, polyphenols, soluble agents, and protective bio-active agents. This composite material approach allows the components to work together synergistically, with the protective agent ensuring sufficient polyphenol delivery to achieve the desired SIRT1 up-regulation effect.

Inventive Principle:
Principle #40Composite materials

Data Source

PatentUS11571438B1Nutraceutical compositions to up-regulate SIRT1 and methods of use
Publication Date: 2023.02.07 AKHAVAN SASAN

AI summary

The present invention discloses a nutraceutical composition for up-regulation of SIRT 1 expression. The nutraceutical composition comprises NMN at in an amount between 300 mg and 500 mg, in an amount of 500 mg, and a soluble agent. The NMN and polyphenol are wrapped in a soluble agent as a protective bio-active agent to increase bioavailability and protect the polyphenol compounds during gut absorption. The invention also discloses a method of preparing a nutraceutical composition by weighing polyphenol at a suitable concentration, mixing the polyphenol with a suitable soluble agent and finally adding NMN to the mixture and blended it to form the nutraceutical composition. The nutraceutical composition up regulates SIRT1 and hence is suitable for treatment of various diseases and used in the form of powder, liquid, tablets, capsules, chewable form, gels, etc.